BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31705948)

  • 21. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.
    Moreira DM; Gershman B; Lohse CM; Boorjian SA; Cheville JC; Leibovich BC; Thompson RH
    World J Urol; 2016 Oct; 34(10):1465-72. PubMed ID: 26914818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma.
    Yang Y; Zhai C; Chang Y; Zhou L; Shi T; Tan C; Xu L; Xu J
    Urol Oncol; 2016 May; 34(5):238.e19-26. PubMed ID: 26749463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.
    Eggener SE; Yossepowitch O; Pettus JA; Snyder ME; Motzer RJ; Russo P
    J Clin Oncol; 2006 Jul; 24(19):3101-6. PubMed ID: 16809736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
    Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
    Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma.
    Jensen HK; Donskov F; Marcussen N; Nordsmark M; Lundbeck F; von der Maase H
    J Clin Oncol; 2009 Oct; 27(28):4709-17. PubMed ID: 19720929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.
    Kim SP; Weight CJ; Leibovich BC; Thompson RH; Costello BA; Cheville JC; Lohse CM; Boorjian SA
    Urology; 2011 Nov; 78(5):1101-6. PubMed ID: 21903243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do renal cell carcinoma patients with brain metastases still need nephrectomy?
    Zhuang W; Li Y; Chen P; Wang J; Liu W; Chen J
    Int Urol Nephrol; 2019 Jun; 51(6):941-949. PubMed ID: 30953259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
    Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
    World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
    Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
    Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT
    Marchioni M; Bandini M; Pompe RS; Martel T; Tian Z; Shariat SF; Kapoor A; Cindolo L; Briganti A; Schips L; Capitanio U; Karakiewicz PI
    BJU Int; 2018 Mar; 121(3):383-392. PubMed ID: 28940649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive intratumoral chemokine (C-C motif) receptor 8 expression predicts high recurrence risk of post-operation clear-cell renal cell carcinoma patients.
    Fu Q; Chang Y; Zhou L; An H; Zhu Y; Xu L; Zhang W; Xu J
    Oncotarget; 2016 Feb; 7(7):8413-21. PubMed ID: 26716905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival analysis of surgically treated renal cell carcinoma: a single Chinese medical center experience from 2002 to 2012.
    Zhang Y; Yu H; Li H
    Int Urol Nephrol; 2015 Aug; 47(8):1327-33. PubMed ID: 26163269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.